Investing.comCodex · 实盘不做把握 9/10
北京时间·🕒 发布 19:36:41时区推断·⟳ 抓取 19:38:00·⚡ 决策 07-28 19:46:47 +8m47s·90.9 天前
Dyne获FDA放行DYNE-302启动FSHD一期临床，但同一催化已推卡
FDA放行DYNE-302 IND本身是Dyne Therapeutics（DYN.US）FSHD管线的早期正面进展。
📄 原文Investing.com↗ 原文
Dyne Therapeutics receives FDA clearance for FSHD trial
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation WALTHAM, Mass. - Dyne Therapeutics, Inc. (NAS…
不做 Dyne Therapeutics（DYN.US）
同一具体催化已在07-28 19:41由ir_page生成★已推卡，本条Investing.com只是重复转述，不再重复交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 medium · price-in 风险 medium ↗
关键理由
- FDA放行DYNE-302 IND本身是Dyne Therapeutics（DYN.US）FSHD管线的早期正面进展。
- 但近72小时已命中同一具体催化且标记为★已推卡，重复转述不应再次出交易卡。
主要风险
- 重复消息若再次交易会重复打扰并重复暴露同一盘前催化风险。
反向证据
- 做多前查反向 · 来源 search_processed_events · 日期 2026-07-28 · 影响 invalidates
命中07-28 19:41已推卡的同一具体催化“Dyne获FDA放行DYNE-302启动FSHD一期临床”，重复转述削弱本条再次交易必要性。
检索:search_processed_events hours=72 limit=200 - 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中与DYNE-302本次IND或商业化量级直接相关的有效新证据；不改变去重结论。
检索:Dyne Therapeutics DYNE-302 FSHD IND FDA clearance FORCE platform revenue cash runway
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,120 字
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation
WALTHAM, Mass. - Dyne Therapeutics, Inc. (NASDAQ:DYN) announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application to begin a Phase 1 clinical trial for DYNE-302 in facioscapulohumeral muscular dystrophy.
DYNE-302 represents the company’s third clinical program using its FORCE platform, following zeleciment rostudirsen for exon 51 Duchenne muscular dystrophy and zeleciment basivarsen for myotonic dystrophy type 1, according to a press release statement.
FSHD is a rare, progressive, inherited muscle disease with no approved therapies. The condition is caused by de-repression of DUX4 in skeletal muscle, leading to muscle damage and loss of function. An estimated 15,000 to 40,000 individuals in the United States and approximately 20,000 to 50,000 in Europe are affected by FSHD.
DYNE-302 uses a TfR1-targeting Fab to deliver an siRNA payload designed to suppress DUX4 expression. In preclinical models, the treatment resulted in knockdown of the DUX4 transcriptome in skeletal muscle, reversal of muscle fiber damage and functional improvement.
The planned Phase 1 trial will be a randomized, placebo-controlled, double-blind, multiple ascending dose study in ambulatory adult individuals with FSHD. The primary endpoint will be safety and tolerability. The trial will also assess pharmacokinetics and pharmacodynamics, including changes in muscle DUX4 transcriptome and plasma KHDC1L levels.
In the first cohort, nine participants will receive three intravenous doses administered every four weeks, randomized 2:1 to DYNE-302 1.5 mg/kg or placebo. Following completion of this cohort, Dyne plans to evaluate higher dosing and less frequent administration. Participants who complete the placebo-controlled period may enter an open-label long-term extension for up to an additional 96 weeks.
The company intends to pursue a traditional approval pathway in the U.S. for DYNE-302.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
WALTHAM, Mass. - Dyne Therapeutics, Inc. (NASDAQ:DYN) announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application to begin a Phase 1 clinical trial for DYNE-302 in facioscapulohumeral muscular dystrophy.
DYNE-302 represents the company’s third clinical program using its FORCE platform, following zeleciment rostudirsen for exon 51 Duchenne muscular dystrophy and zeleciment basivarsen for myotonic dystrophy type 1, according to a press release statement.
FSHD is a rare, progressive, inherited muscle disease with no approved therapies. The condition is caused by de-repression of DUX4 in skeletal muscle, leading to muscle damage and loss of function. An estimated 15,000 to 40,000 individuals in the United States and approximately 20,000 to 50,000 in Europe are affected by FSHD.
DYNE-302 uses a TfR1-targeting Fab to deliver an siRNA payload designed to suppress DUX4 expression. In preclinical models, the treatment resulted in knockdown of the DUX4 transcriptome in skeletal muscle, reversal of muscle fiber damage and functional improvement.
The planned Phase 1 trial will be a randomized, placebo-controlled, double-blind, multiple ascending dose study in ambulatory adult individuals with FSHD. The primary endpoint will be safety and tolerability. The trial will also assess pharmacokinetics and pharmacodynamics, including changes in muscle DUX4 transcriptome and plasma KHDC1L levels.
In the first cohort, nine participants will receive three intravenous doses administered every four weeks, randomized 2:1 to DYNE-302 1.5 mg/kg or placebo. Following completion of this cohort, Dyne plans to evaluate higher dosing and less frequent administration. Participants who complete the placebo-controlled period may enter an open-label long-term extension for up to an additional 96 weeks.
The company intends to pursue a traditional approval pathway in the U.S. for DYNE-302.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。